Description

Lonza Group AG, founded in 1897 and headquartered in Basel, Switzerland, operates as a global supplier of specialized products and services. The company primarily serves the pharmaceutical, biotechnology, and nutrition sectors. Its operations are divided into four main segments: Biologics: This division provides end-to-end contract development and manufacturing (CDMO) services specifically for biopharmaceutical products. Small Molecules: Acting as an integrated partner, this segment focuses on the development and production of small molecule active pharmaceutical ingredients (APIs) and their chemical intermediates. Cell and Gene: This segment is dedicated to advancing and industrializing manufacturing processes for cell and gene therapies. It offers extensive CDMO services for a wide array of treatments, including allogeneic, autologous, and exosome-based cell therapies, as well as viral vector gene therapies. Additionally, it supplies crucial raw materials and enabling technological solutions vital for cell and gene therapy, injectable drugs, vaccines, and the broader biomanufacturing industry. Capsules and Health Ingredients: This division delivers innovative capsule solutions, various dosage forms, and a selection of health ingredients to pharmaceutical and nutraceutical customers.